CapsoVision, Inc (CV) CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
Sector: Electromedical & Electrotherapeutic Apparatus
Industry: Medical - Devices
CapsoVision, Inc. NASDAQ:CV Healthcare · Medical - Equipment & Services
Mkt Cap $363.43M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026
CapsoVision will release third quarter 2026 financial results on Thursday, November 12, 2026, after market close.
The company will host a conference call and webcast at 4:30 pm ET the same day to discuss results and provide a corporate update.
This is a scheduling notice only; no financial figures or guidance were included.
• 3d ago AI analysis › Press Release
CapsoVision to Present at the 20th Annual LD Micro Main Event
CapsoVision will present at the 20th Annual LD Micro Main Event on October 21, 2026, at 9:00-9:25 am PT in Los Angeles, with a webcast streamed live.
CEO Johnny Wang, SVP of Finance David Garcia, and SVP of Global Sales Doug Atkinson will deliver the presentation and hold 1x1 investor meetings.
The release contains no new financial or clinical data; it is a standard conference appearance notice for the capsule endoscopy maker.
• 19d ago AI analysis › Press Release
CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®
CapsoVision received FDA clearance for AI Highlights, an AI-assisted reading tool for its CapsoCam Plus capsule endoscopy system, cleared September 25, 2026.
The tool flags suspected abnormal lesions to reduce physician review time and integrates with CapsoView and CapsoCloud workflows; it follows an earlier international launch including the EU under MDR.
The clearance supports physician efficiency and capsule endoscopy adoption, though the tool supplements rather than replaces diagnostic interpretation.
• 1mo ago AI analysis › Press Release
CapsoVision to Participate in Upcoming Investor Conferences
CapsoVision (NASDAQ: CV) announced that CEO Johnny Wang, SVP of Finance David Garcia, and SVP of Global Sales Doug Atkinson will participate in two upcoming investor conferences in New York City.
The company will post an on-demand presentation for the H.C. Wainwright 28th Annual Global Investment Conference beginning September 11, 2026, with 1x1 investor meetings on September 14, followed by 1x1 meetings at the 5th Annual ROTH Healthcare Opportunities Conference on September 29.
The on-demand presentation will remain available on the company's investor relations website for 90 days; the release contains no new financial, clinical, or regulatory information and is routine investor-outreach scheduling.
• 1mo ago AI analysis › Press Release ⚠ 3
CapsoVision Reports Second Quarter 2026 Financial Results
CapsoVision reported Q2 2026 revenue of $3.6 million, up 10% year-over-year, driven by increased capsule volume despite a 3% decline in average selling price.
Gross margin fell to 51% from 55% due to competitive pricing and tariffs, while operating expenses rose 46% to $9.5 million, resulting in a net loss of $7.5 million.
The company launched its AI Highlights feature in the EU and anticipates FDA clearance by Q3, while securing a $100 million at-the-market equity offering facility and appointing Dr. David S. Shields to the board.
• 2mo ago AI analysis › Press Release
CapsoVision® Announces International Launch of AI Highlights
CapsoVision announced the international launch of AI Highlights, an AI-assisted review feature for its CapsoCam Plus capsule endoscopy system, initially targeting markets including the European Union.
The tool is designed to identify frames with suspected clinically relevant findings during video processing, integrating with the CapsoView software and CapsoCloud platform to enhance physician workflow.
CEO Johnny Wang highlighted the feature's potential to improve physician efficiency and reading performance, though the update is not yet FDA cleared and remains unavailable for sale in the United States.
• 2mo ago AI analysis › Press Release
CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026
CapsoVision announced it will release its second quarter 2026 financial results on Thursday, August 13, 2026, after the market closes.
The company will host a conference call and live webcast at 4:30 pm ET on the same day to discuss the results and provide a corporate update.
Investors can access the call via dial-in or the investor relations section of the company's website.
• 3mo ago AI analysis › Press Release
CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D., to Board of Directors
CapsoVision appointed Dr. David S. Shields to its Board of Directors, effective July 1, 2026. Dr. Shields is a board-certified gastroenterologist with over 40 years of experience and succeeds Dr. Joanne Imperial, who steps down to remain as a clinical consultant.
Dr. Shields has served as a clinical advisor to the company since 2017 and brings extensive experience in capsule endoscopy from his time at Stanford University and the Palo Alto VA Health Care System.
The appointment comes as CapsoVision approaches key milestones, including the anticipated commercial launch of its AI-assisted reading feature and the planned 2027 esophageal varices study.
• 4mo ago AI analysis › Press Release
CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D.
globenewswire.com • 4mo ago Press Release ⚠ 3
CapsoVision Reports First Quarter 2026 Financial Results
CapsoVision reported Q1 2026 revenue of $2.8 million, effectively flat year-over-year, driven by a 3% decline in capsule volume offset by a slight increase in average selling price.
Gross margin contracted to 48% from 54% due to U.S. trade policy impacts, while operating expenses rose 22% to $8.4 million, primarily from R&D for new CMOS sensors and clinical trials.
The company closed a $14 million private placement in March, bringing total cash and equivalents to $17.9 million, and highlighted progress on its AI-assisted reading feature and pipeline programs.
• 5mo ago AI analysis › Press Release ● Major
CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026
globenewswire.com • 6mo ago 
